Weekly docetaxel, cisplatin, and irinotecan (TPC): Results of a multicenter phase II trial in patients with metastatic esophagogastric cancer

Annals of Oncology

Volumn 20, Issue 3, 2009, Pages 475-480

  Enzinger, Peter C ^a   Ryan, D P ^b   Clark, J W ^b   Muzikansky, A ^b   Earle, C C ^a   Kulke, M H ^a   Meyerhardt, J A ^a   Blaszkowsky, L S ^b   Zhu, A X ^b   Fidias, P ^b   Vincitore, M M ^a   Mayer, R J ^a   Fuchs, C S ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; Esophageal cancer; Gastric cancer; Irinotecan

Indexed keywords

CISPLATIN; DOCETAXEL; IRINOTECAN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBOLISM; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBINOPATHY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; STOMACH NEOPLASMS; TAXOIDS;

EID: 61649104588     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn658     Document Type: Article

References (22)

1. Dank M, Zaluski J, Barone C et al. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients. J Clin Oncol 2005; 23: A4003.
2. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.
3. Kang Y, Kang WK, Shin DB et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. J Clin Oncol 2006; 24: LBA4018.
4. Ilson DH, Saltz L, Enzinger P et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999; 17: 3270-3275.
5. Ajani JA, Baker J, Pisters PW et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002; 94: 641-646.
6. Chou TC, Motzer RJ, Tong Y et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-1524.
7. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
8. Kaplan E, Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
9. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-151.
10. Lorenzen S, Duyster J, Lersch C et al. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: Final results of a phase II trial. Br J Cancer 2005; 92(2129): 33.
11. Giordano KF, Jatoi A, Stella PJ et al. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: A phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006; 17: 652-656.
12. Price T, Waters J, Cunningham D. Palliative chemotherapy in oesophageal carcinoma: Evidence for clinical benefit. Proc Annu Meet Am Soc Clin Oncol 2000; 19: A1228.
13. Boku N, Ohtsu A, Shimada Y et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17: 319-23.
14. Ilson D, Graham C, Steinbrenner I et al. A multicenter phase II trial of weekly irinotecan and cisplatin in advanced esophageal and GE junction cancer. Proceedings of the 2004 Gastrointestinal Cancers Symposium 2004 (Abstr 13).
15. Koizumi W, Kurihara M, Satoh A et al. Phase I/II study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer. Anticancer Res 2005; 25: 1257-1262.
16. Kulke MH. The treatment of advanced gastric cancer: In search of the right combination. J Clin Oncol 2000; 18: 2645-2647.
17. Lordick F, von Schilling C, Bernhard H et al. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer 2003; 89: 630-633.
18. Park SR, Chun JH, Yu MS et al. Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. Br J Cancer 2006; 94: 1402-1406.
19. Di Lauro L, Nunziata C, Arena MG et al. Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. Br J Cancer 2007; 97: 593-597.
20. Ridwelski K, Fahlke J, Kettner E et al. Docetaxel-cisplatin (DC) versus 5- fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study. J Clin Oncol 2008; 26: (Abstr 4512).
21. Rougier P, Oba K. (GASTRIC) GAASTRtIC: Meta-analyses of randomized trials assessing the interest chemotherapy in advanced gastric cancer. J Clin Oncol 2008; 26: (abstr 4563).
22. Enzinger PC, Ryan DP, Regan EM et al. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. Proceedings of the 2008 Gastrointestinal Cancers Symposium 2008 (Abstr 97).